Invokana Side Effects Cited In Lawsuit as Potential Cause of Heart Attack and Stroke During Clinical Trials for the Drug

May 01, 2016 – – TheProductLawyers.com comments on Invokana clinical study results and a New York Times article that focused on the failure of Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson Corporation, to identify the potential risks of heart attack and stroke on the warning label for Invokana, a new-generation, type-2 diabetes drug. The U.S. Food and Drug Administration (FDA) approved Invokana in March of 2013, and was the first drug in a number of similar sodium-glucose co-transporter 2 (SGLT2) inhibitor drugs that were approved by the FDA and released on the market to treat patients suffering from type-2 diabetes.

It has been reported by the FDA that 13 patients using Invokana as part of the initial clinical trials for the drug suffered from a major cardiac event such as a heart attack or stroke, within the initial treatment period of 30 days. After this first 30 days of treatment, however, the risk of heart attack or stroke seemed to have quickly evened out.

Due to the alleged heightened risks that were highlighted during the clinical trials for the drug, the FDA is requiring the drug’s manufacturer, Johnson & Johnson, to initiate a number of subsequent studies, that includes a more thorough investigation to fully understand if Invokana actually does increase the risks of heart attack and stroke while taking the drug.

Heart attacks are precipitated when the blood flow to the heart is blocked, usually because of a blood clot. The heart needs oxygen that is carried to it by proper and unfettered blood flow. Since the blood clot prevents the heart from getting the oxygen it requires to function properly, the heart muscle begins to die, and may subsequently result in significant tissue damage. Along with this damage and the decrease in proper heart function, a heart attack is possible that results in the death of the patient.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009671